AstraZeneca plc 6.8% Potential Upside Indicated by Barclays Capital

Broker Ratings
[shareaholic app="share_buttons" id_name="post_below_content"]

AstraZeneca plc using EPIC/TICKER code (LON:AZN) had its stock rating noted as ‘Reiterates’ with the recommendation being set at ‘OVERWEIGHT’ today by analysts at Barclays Capital. AstraZeneca plc are listed in the Health Care sector within UK Main Market. Barclays Capital have set a target price of 9300 GBX on its stock. This now indicates the analyst believes there is a possible upside of 6.8% from the opening price of 8707 GBX. Over the last 30 and 90 trading days the company share price has increased 159 points and increased 445 points respectively. The 1 year high stock price is 10120 GBX while the 52 week low for the stock is 5871 GBX.

AstraZeneca plc has a 50 day moving average of 8,768.12 GBX and a 200 day moving average of 7,919.13. There are currently 3,314,307,303 shares in issue with the average daily volume traded being 2,185,913. Market capitalisation for LON:AZN is £113,931,375,252 GBP.

Twitter
LinkedIn
Facebook
Email
Reddit
Telegram
WhatsApp
Pocket
Find more news, interviews, share price & company profile here for:
    AstraZeneca Plc commits $3.5 billion to boost US research and manufacturing by 2026, creating jobs and expanding its innovation footprint.
    AstraZeneca and Amgen's Tezspire shows promise in reducing nasal polyp size and congestion, offering hope for chronic rhinosinusitis patients.
    AstraZeneca's Wainzua gains CHMP backing for EU approval in treating ATTRv-PN, marking a potential breakthrough with self-administered therapy.

      Search

      Search